Latest Regulatory Approval News

Lakes Blue Energy has temporarily halted gas flow testing at its Wombat-5 well to conduct extended pressure analysis, planning a perforation program to enhance production prospects.

Chimeric Therapeutics Limited has announced a significant 100-to-1 security consolidation affecting shares, options, and performance rights, pending shareholder approval and set for implementation in April 2026.

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

Neometals Ltd has released a positive scoping study for its Ironclad gold deposit at the Barrambie Gold Project, outlining a rapid production pathway with potential output of up to 11,000 ounces of gold within a year.

Infotrust has agreed to acquire Canberra-based Catalyst Cyber, marking a strategic push into federal government cyber security markets with an expected earnings boost from the deal.

Magnetic Resources NL is set to be acquired by Genesis Minerals Limited, with outstanding options cancelled for cash following an ASX waiver. Performance rights will vest and be exercised prior to the scheme’s record date.

Kina Securities Limited has updated its dividend announcement to include the Dividend Reinvestment Plan pricing details for the six months ending December 2025, offering shareholders clarity on payment and reinvestment options.

Core Lithium has taken the final investment decision to restart its Finniss Lithium Project, backed by a $307 million diversified funding package and strategic partnerships. The project targets a 20-year mine life with low operating costs and significant growth potential.

Strike Resources has agreed to sell a further 28.52% indirect stake in its Apurimac Iron Ore Project to JE United Ltd for A$5.5 million, while securing a US$5 million credit facility to accelerate project development and iron ore marketing.

Imugene Limited has launched a $20 million equity raising comprising a $12 million placement and an $8 million Share Purchase Plan, alongside issuing options, convertible notes, and warrants to support its azer-cel clinical program.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.